Peregrine Pharmaceuticals Investor Alert: Lawsuit alleges Misleading Statements

A lawsuit was filed for certain investors in shares of Peregrine Pharmaceuticals shares over alleged securities laws violations. Deadline: November 27, 2012 and NASDAQ-PPHM stockholders should contact the Shareholders Foundation.
 
 
mail@shareholdersfoundation.com
mail@shareholdersfoundation.com
 
Spread the Word
Listed Under

Tags:
Peregrine Pharmaceuticals
NASDAQ:PPHM
Securities Class Action
Class Action
Lawsuit

Industrys:
Business
Finance

Location:
San Diego - California - US

Oct. 15, 2012 - PRLog -- An investor in shares of Peregrine Pharmaceuticals  filed a lawsuit in the U.S. District Court, Central District of California against Peregrine Pharmaceuticals over alleged securities laws violations in certain allegedly false and misleading financial statements.

If you purchased shares of Peregrine Pharmaceuticals  between July 17, 2012 and September 26, 2012, you have certain options and there are short and strict deadlines running. Deadline: November 27, 2012. NASDAQ-PPHM investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

According to the complaint the plaintiff alleges on behalf of all persons who purchased Peregrine Pharmaceuticals  common stock between July 17, 2012 and September 26, 2012, that Peregrine Pharmaceuticals and certain of its officers violated the Securities Exchange Act of 1934 by issuing between July 17, 2012 and September 26, 2012 allegedly materially false and misleading statements regarding Peregrine Pharmaceuticals’ Bavituxmab Phase II Second-Line Non-Small Cell Lung Cancer Trial.

Specifically, so the plaintiff, Peregrine Pharmaceuticals allegedly made false and/or misleading statements and/or failed to disclose that there were major discrepancies between some patient sample test results and patient treatment code assignments in the Company's Phase II Trial.

On September 24, 2012 Peregrine Pharmaceuticals announced that it had discovered major discrepancies in treatment group cofding by an independent third-party vendor responsible for distribution of blinded investigational product used in its bavituximab phase II second-line non-small cell lung cancer trial.

Shares of Peregrine Pharmaceuticals  dropped from $5.36 per share on September 21, 2012 to as low as $0.99 on September 28, 2012.

Those who purchased shares of Peregrine Pharmaceuticals  between July 17, 2012 and September 26, 2012, have certain options and there are short and strict deadlines running. Deadline: November 27, 2012. NASDAQ-PPHM investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
End
Source:
Email:***@shareholdersfoundation.com Email Verified
Phone:+1-(858)-779-1554
Zip:92108
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse



Like PRLog?
9K2K1K
Click to Share